Sanofi-Aventis has pulled out of developing Oxford BioMedica's novel cancer vaccine TroVax, but will pay the UK company £34 million to develop four preclinical ocular therapies.
Oxford BioMedica regains the worldwide rights to TroVax after its co-development partner Sanofi-Aventis announced this week that it was stopping...